Recent Updates — TEM

Tempus AI entered into agreements with Bristol-Myers Squibb (BMS) and Pathos to expand the use of its de-identified multimodal real-world data, software, and machine learning models. The transaction includes a Statement of Work with BMS for oncology data access and analysis services, valued at $137.5 million over five years ending December 2031. Additionally, Tempus licensed neurology data and an agentic tool to Pathos for use in collaboration with BMS, generating up to $55 million in fees based on the delivery of 500,000 patient records over a five-year term. The agreements were approved by a special committee of disinterested directors due to related-party overlaps between Tempus and Pathos. Tempus AI operates in the healthcare technology sector, providing data analytics and artificial intelligence solutions for precision medicine.

Tempus AI reported Q2 2026 revenue of $382.5 million, a 22% year-over-year increase, driven by 31% growth in oncology volume and 36% growth in Data Licensing & Modeling. The company achieved GAAP net income of $5.6 million and Adjusted EBITDA of $8.0 million. It raised full-year 2026 revenue guidance to $1.595–$1.605 billion and expects ~$65 million in Adjusted EBITDA. Tempus completed a $460 million offering of convertible senior notes due 2032, signed approximately $200 million in new data licenses, and received FDA approval for its xT Tumor Only assay. Additionally, the company announced an agreement to acquire Personalis for ~$1.5 billion.

Tempus AI, Inc. entered into a Merger Agreement on July 20, 2026, to acquire Personalis, Inc. through a two-step merger involving its subsidiaries. The transaction consideration includes Tempus Class A Common Stock based on a variable exchange ratio determined by Tempus's stock price, with an option for Tempus to pay cash for up to 50% of the outstanding Personalis shares at $16.25 per share. Tempus AI, Inc. operates in the healthcare technology and data-driven precision medicine industry through its AI-driven platform.

Tempus AI, Inc. entered into a definitive agreement to acquire Personalis, Inc. for a total enterprise value of $1.5 billion. Personalis shareholders will receive $16.25 per share in a transaction structured as 100% stock, with Tempus having an option to elect up to 50% cash consideration. The deal is expected to close in late 2026 or early 2027 and is subject to shareholder and regulatory approvals. Tempus AI, Inc. is a technology company that uses artificial intelligence to advance precision medicine and patient care.